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Edited by Veli-Pekka LehtoAbstract Though phospholipase C PLCc2 is known to play an
important role in platelet activation by collagen and ﬁbrinogen,
its importance in GPIb-mediated platelet activation is less well
understood. To better understand the role of PLCc2 in GPIb-
mediated adhesion and thrombus formation, we examined the
ability of wild-type and PLCc2- deﬁcient murine platelets to
spread on immobilized von Willebrand factor (VWF) under
static conditions, and to attach to and form thrombi on VWF
under conditions of arterial shear. While absence of PLCc2 had
only a minimal eﬀect on platelet adhesion to immobilized VWF,
its absence impaired spreading and profoundly aﬀected thrombus
growth and stability on VWF.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Platelet activation at sites of vascular injury triggers the
rapid hydrolysis of the minor membrane-anchored phospho-
lipid, phosphatidylinositol 4,5 bisphosphate (PIP2) – a reaction
that is carried out by members of the phospholipase C (PLC)
family of lipid-hydrolyzing enzymes. PLC activity results in the
generation of the second messengers diacylglycerol (DAG) and
inositol 1,4,5-trisphosphate (IP3) [1]. DAG promotes the ac-
tivation of certain isoforms of protein kinase C (PKC), while
IP3 binds to and controls the permeability of speciﬁc calcium
channels present on intracellular membranes of the endoplas-
mic reticulum and the dense tubular system, which sequester
most of the intracellular calcium in resting cells.
Mammalian cells contain eleven genes that encode phos-
pholipase C (PLC) isozymes, including four members each of
the PLC-b and PLC-d subfamilies, the newly discovered
PLCe, and two isoforms of PLCc [1]. While the b isozymes
ﬁgure prominently in signal transduction by Gqa protein-
coupled receptors, the PLCc isoforms, c1 and c2, are
regulated by tyrosine phosphorylation [2], and function* Corresponding author. Fax: +1-414-937-6284.
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and immunoreceptor tyrosine-based activation motif
(ITAM)-linked immunoglobulin superfamily receptors, in-
cluding T and B cell receptors and Fc receptors [3]. Whereas
PLCc1 is widely distributed, the expression of PLCc2 is
limited to cells of the hematopoietic lineage. Consistent with
their expression patterns, PLCc1 deﬁciency results in em-
bryonic lethality [4], while mice genetically deﬁcient in
PLCc2 exhibit defects in B cell development and function,
natural killer cell activation, and mast cell FceR signaling [5].
In addition, PLCc2-deﬁcient mice have platelet defects, suﬀer
from spontaneous subcutaneous hemorrhaging during em-
bryogenesis, and gastrointestinal and intraperitoneal bleeding
during adulthood [5].
In order for platelets to control bleeding, they must undergo
a sequential progression of adhesive and signaling events that
are initiated, at least in part, by interaction of the platelet
plasma membrane glycoprotein GPIb/V/IX complex with von
Willebrand factor (VWF) immobilized on exposed collagen
surfaces [6]. Shear forces applied to the GPIb complex, which
is linked to the membrane skeleton on the inner face of the
plasma membrane [7], result in the activation of one or more
Src family kinases [8] followed by transient, low magnitude
calcium oscillations that allow initially adherent platelets to
undergo cytoskeletal rearrangements, spread, and stably arrest
[9]. Sustained calcium mobilization serves to amplify these
initial responses by promoting integrin activation, granule se-
cretion, and recruitment of additional platelets to the site of
vascular injury [10,11].
Though PLCc2 is known to play an important role in
platelet activation by collagen [5,12,13] and ﬁbrinogen [14,15]
(via GPVI and the GPIIb-IIIa complex, respectively), the im-
portance of PLC-dependent phosphoinositide turnover in
GPIb-mediated platelet activation is just now beginning to be
unraveled. Mangin et al. [16] recently reported that the small
amount of IP3 that is generated downstream of GPIb-medi-
ated platelet adhesion to immobilized VWF under static con-
ditions, as well as the low-level calcium transients and
cytoskeletal changes that follow, can be completely inhibited
by the pan-PLC pharmacological antagonist, U73122. Inter-
estingly, these early activation responses do not appear to in-
volve any of the PLCb isoforms, and were signiﬁcantly
reduced, but not completely abolished, in PLCc2-deﬁcient
platelets, suggesting that both PLCc2 and at least one other
isoform of PLC are involved in the early stages of GPIb-
mediated platelet activation, at least under static conditions.blished by Elsevier B.V. All rights reserved.
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of GPIb and GPIIb-IIIa [10,17]. It is not known which
(or if both) receptor requires PLCc2 to transduce VWF-
dependent signals or whether the PLCc2 requirement
extends to thrombus formation on VWF under shear con-
ditions. To address these issues, we compared the abilities of
wild-type and PLCc2-deﬁcient platelets to adhere to and
either spread or form thrombi on VWF under static vs.
shear conditions, respectively. Under static conditions,
PLCc2 was more important for spreading than for adher-
ence of platelets to immobilized VWF. Under shear condi-
tions, PLCc2 contributed profoundly to growth and stability
of platelet thrombi on VWF. Our ﬁndings suggest that the
major contribution of PLCc2 following platelet interactions
with VWF is to amplify GPIIb-IIIa-mediated outside-in
signals.Fig. 1. PLCc2-deﬁcient murine platelets adhere to, but have impaired spreadi
adhesion to VWF. Calcein AM-labeled platelets were incubated under static c
been coated with 10 lg/mL human VWF or bovine serum albumin (BSA) in th
calculated by measuring the ﬂuorescence of bound platelets total ﬂuorescen
wells and are representative of two independent experiments. No appreciabl
VWF was observed at any of the time points examined. (B) PLCc2-deﬁcient
(PLC)c2= (lower panels) washed platelets were allowed to spread on gla
botrocetin under static conditions at 37 C in the presence or absence of 2 mM
VWF-coated slides. The panels shown are representative ﬁelds from two ind
pixels covered by each platelet, was determined from digitized images using
examined. Results are presented as the mean surface areaS.E.M. of two ind
platelets was signiﬁcantly (P < 0:0001) reduced compared to WT platelets.2. Materials and methods
2.1. Platelet adhesion and spreading on VWF under static conditions
Adhesion and spreading of washed wild-type (WT) and PLCc2-de-
ﬁcient [5] murine platelets on human VWF (huVWF) was performed
essentially as described previously [18]. RGDW peptide, which eﬀec-
tively inhibits GPIIb-IIIa-mediated platelet spreading, was used to
determine the surface area covered by attached, but not spread,
platelets. Since rodent GPIIb-IIIa is relatively less sensitive to inhibi-
tion by RGD peptide than is human GPIIb-IIIa (IC50¼ 1.65 versus
0.04 mM, respectively) [19,20], it was used at a concentration of 2 mM,
which has previously been shown to inhibit VWF/botrocetin-induced
aggregation and spreading of murine platelets [18].
2.2. Thrombus formation on VWF under conditions of arterial shear
Platelet thrombus formation on human VWF under ﬂow was stud-
ied using a parallel-plate ﬂow chamber as described previously [18].
Brieﬂy, mepacrine-labeled, red blood cell-reconstituted platelets were
perfused through the chamber using a constant rate syringe pump at ang on, immobilized VWF. (A) PLCc2-deﬁcient platelets exhibit normal
onditions at 37 C for indicated time points in microtiter wells that had
e presence or absence of 5 U/ml botrocetin (Bot). Percent adhesion was
ce 100. Results are presented as percent adhesionS.D. of triplicate
e diﬀerence in percent adhesion of WT versus (PLC)c2= platelets to
platelets exhibit impaired spreading on VWF. WT (upper panels) and
ss slides coated with human VWF (10 lg/ml) in presence of 5 U/ml
RGDW. Images were taken 60 min following addition of platelets to
ependent experiments. (C) Platelet surface area, deﬁned as number of
Metamorph software. At least 150–200 platelets per condition were
ependent experiments. Note that the extent of spreading by (PLC)c2=
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formation was visualized at 40 magniﬁcation, recorded on videotape,
digitized using Pinnacle Studio Software (Pinnacle Systems Inc.,
Mountain View, CA) and analyzed oﬄine.
Thrombus size was analyzed using still images acquired from digi-
tized recordings captured at 1, 2 and 3 min after initiation of ﬂow. The
number of pixels covered by the smallest platelet aggregate formed by
PLCc2= platelets after 1 min of ﬂow was arbitrarily assigned as the
cutoﬀ value for deﬁnition of a thrombus. Surface areas of individual
platelet aggregates and thrombi formed by WT and PLCc2= plate-
lets at 1, 2 and 3 min after initiation of ﬂow were determined using
Metamorph software. The mean size of individual WT and PLCc2=
platelet thrombi, as well as the combined surface areas of all thrombi
in a given experiment, were normalized for each time point to that of
the largest thrombus so that data from three separate experiments
could be compared. Statistical analysis of means standard error was
performed using an unpaired Student’s t test.3. Results and discussion
3.1. PLCc2-deﬁcient murine platelets adhere to, but spread
poorly on, immobilized VWF
Adhesive interactions between human GPIb (huGPIb) and
huVWF can be examined under static conditions by ‘‘acti-Fig. 2. PLCc2-deﬁciency aﬀects the rate and extent of murine platelet thrombu
formation by WT (upper panels) and (PLC)c2= (lower panels) platelets. W
pre-coated with 40 lg/ml human VWF at arterial wall shear rates of 1500 s1
1, 2 and 3 min after initiation of ﬂow and are representative of three indepe
larger in wild-type versus (PLC)c2= platelets. (B) Photographic images w
termined as described in Section 2. Results are presented as a scatter plot o
(PLC)c2= (open triangles) platelets at 1, 2 and 3 min following initiati
Horizontal lines represent mean thrombus size. (C) Thrombus sizes in each of
analysis as described in Section 2. Results are presented as mean thrombus s
platelets formed signiﬁcantly smaller thrombi (P < 0:01) after 2 and 3 min ovating’’ VWF immobilized on glass or plastic surfaces with
conformational modiﬁers such as ristocetin or botrocetin.
Previous studies [16,21] have shown that botrocetin is also able
to support the binding of huVWF to murine platelets, resulting
in shape change and aggregation. As shown in Fig. 1A, wild-
type and PLCc2= murine platelets bound to a similar extent
to immobilized huVWF/botrocetin, conﬁrming a recent report
[16] that initial adhesive interactions between GPIb and VWF
do not require PLCc2. This group also found that PLCc2-
deﬁcient platelets are slower to extend ﬁlopodia following
platelet binding to immobilized VWF than are their wild-type
counterparts. To examine the longer-term eﬀects of PLCc2
deﬁciency on GPIb-mediated platelet activation, we evaluated
both ﬁlopodia and lamellipodia formation 60 min after VWF
binding. Though the number of ﬁlopodia was not statistically
diﬀerent at this later time point (data not shown), lamellipodia
formation was signiﬁcantly inhibited in PLCc2= platelets,
with spreading reduced to the degree achieved by wild-type
platelets in the presence of RGDW peptide (Fig. 1B and C),
which inhibits GPIIb-IIIa-mediated adhesive interactions.
Since lamellipodia formation and platelet spreading on VWF
require interaction of activated GPIIb-IIIa with the VWF C1s formation on VWF under conditions of arterial shear. (A) Thrombus
ashed and RBC-reconstituted platelets were perfused over glass slides
in a parallel-plate ﬂow chamber. The images shown are frames frozen at
ndent experiments. Note that thrombi formed more rapidly and grew
ere digitized and the surface area covered by each thrombus was de-
f the sizes of individual thrombi formed by WT (ﬁlled triangles) and
on of ﬂow and are representative of three independent experiments.
three diﬀerent experiments were normalized and subjected to statistical
ize S.E.M. of three independent experiments. Note that (PLC)c2=
f ﬂow, relative to wild-type platelets.
Fig. 3. A model showing events in GPIb-mediated thrombus formation to which PLCc2 contributes.
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not important for initial GPIb-mediated platelet adhesion to
immobilized VWF, contributes importantly in amplifying
GPIIb-IIIa mediated platelet spreading and lamellipodia for-
mation on VWF.
3.2. PLCc2 deﬁciency aﬀects the rate and extent of murine
platelet thrombus formation on VWF under conditions of
arterial shear
We have recently shown that washed, red blood cell-recon-
stituted murine platelets can tether to, become activated by,
and form thrombi on huVWF under conditions of arterial
shear [18], thereby obviating the need for added botrocetin as a
conformational modiﬁer. These conditions are similar to those
previously employed to examine huVWF/huGPIb interactions
[22,23], and likely involve GPIb-mediated activation events
that lead to secretion of (1) soluble agonists such as ADP and
(2) adhesive proteins such as VWF and ﬁbrinogen that to-
gether support thrombus formation in the absence of exoge-
nously added plasma proteins. To examine the eﬀects of
PLCc2 deﬁciency on thrombus formation under these condi-
tions, we perfused wild-type and PLCc2= murine platelets
over immobilized huVWF at arterial shear rates. As shown in
Fig. 2A, wild-type platelets began to form aggregates within
one minute following the initiation of ﬂow, and these aggre-
gates rapidly coalesced to form large, stable thrombi. In
contrast, PLCc2= platelets were observed to form platelet-
platelet contacts only transiently, limiting both the rate and
extent of thrombus growth in a statistically signiﬁcant fashion
(Fig. 2B and C). These data demonstrate that PLCc2 con-
tributes importantly to the growth of platelet thrombi on VWF
under conditions of arterial shear.
The observation that PLCc2-deﬁcient platelets can still form
thrombi following exposure to immobilized VWF, albeit
smaller and more transiently (see supplemental online video to
Fig. 2A) than those formed by wild-type platelets, suggests
that other PLC isoforms may be involved in this process.
Consistent with this notion, we found that pharmacologicalinhibition of total PLC activity by U73122, a PLC antagonist
[24] while not aﬀecting stable adhesion, completely abolished
thrombus formation by human platelets on VWF (data not
shown). Since PLCb isoforms do not appear to be involved in
GPIb-mediated platelet activation [16], it is likely that PLCc1,
though expressed at much lower levels than is PLCc2 [12], may
compensate for the absence of PLCc2 in supporting thrombus
formation on VWF. In fact, PLCc1 has recently been shown to
function downstream of GPVI following platelet exposure to
collagen [12]. The contribution of PLCc1 to GPIb- and GPIIb-
IIIa-mediated signal transduction using genetic models of
PLCc1 deﬁciency is currently under investigation.
In conclusion, our data extend the recent ﬁndings of Mangin
et al. [16] and strongly support the concept that PLCc2, while
playing only a minor role in initial platelet adhesion to im-
mobilized VWF, contributes importantly to platelet spreading
and platelet thrombus formation on VWF under conditions of
arterial shear. Since eﬃcient thrombus formation involves se-
cretion of secondary mediators such as ADP and binding of
soluble ﬁbrinogen and VWF to activated GPIIb-IIIa com-
plexes, it would appear that the major contribution of PLCc2
is as an ampliﬁer of outside-in signals emanating from GPIIb-
IIIa (see schematic in Fig. 3). Further studies will be required
to delineate the potential for other PLC isoforms to contribute
to platelet activation, adhesion, and thrombus formation
in vivo.
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